2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 52(2018) N 3 p. 436-445; DOI 10.1134/S0026893318030032 Full Text

D.E. Demin1,2, A.V. Bogolyubova1,3, D.V. Zlenko3, A.N. Uvarova1,3, A.V. Deikin4, L.V. Putlyaeva1, P.V. Belousov1, N.A. Mitkin1, K.V. Korneev1,3, E.N. Sviryaeva1, I.V. Kulakovskiy1,5, K.A. Tatosyan1, D.V. Kuprash1,2,3, A.M. Schwartz1,2*

The Novel Short Isoform of Securin Stimulates the Expression of Cyclin D3 and Angiogenesis Factors VEGFA and FGF2, but Does Not Affect the Expression of MYC Transcription Factor

1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia
2Moscow Institute of Physics and Technology, Dolgoprydny, Moscow oblast, 141701 Russia
3Faculty of Biology, Moscow State University, Moscow, 119234 Russia
4Institute of Gene Biology, Russian Academy of Sciences, Moscow, 119334 Russia
5Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, 119991 Russia

Received - 2017-09-26; Accepted - 2017-11-16

Pituitary tumor-transforming gene-1 (PTTG1) encodes securin, a multifunctional protein involved in development of various types of cancer. Securin participates in the regulation of sister chromatids separation and the expression of multiple genes involved in the control of the cell cycle, metabolism, and angiogenesis. In several human cell lines, we have found a novel short isoform of securin mRNA, which does not contain exons 3 and 4. After the translation of this new mRNA, a shortened protein is produced that, like the full-size form, is able to activate the transcription of cyclin D3 gene (CCND3), which controls the G1/S transition and angiogenesis factors VEGFA (vascular endothelial growth factor), and FGF2 (fibroblast growth factor 2) in HEK293 cells. However, unlike the full-size protein, the short isoform of PTTG1 does not affect the MYC gene expression because it lacks the DNA-binding domain, which is needed for its interactions with the MYC promoter. Furthermore, the short form of securin does not influence the expression of MYC transcriptional targets, such as TP53 and IL-8. Thus, we found a novel isoform of securin which is able to activate a more restricted repertoire of genes compared to the full-size protein.

PTTG1, securin, alternative splicing, cyclin D3, FGF2, VEGF, transcription regulation